Clinical Trial Update: Etelcalcetide to Treat Secondary Hyperparathyroidism in Hemodialysis Patients With Chronic Kidney Disease-Mineral and Bone Disorder [Phase 2]

View source ↗

Summary

Phase 2 results update for etelcalcetide in treating secondary hyperparathyroidism in hemodialysis patients with CKD-MBD. Results were posted in April 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperparathyroidism

Drugs mentioned

• Etelcalcetide (etelcalcetide)

Snippet

Sponsor: KAI Pharmaceuticals | Conditions: Secondary Hyperparathyroidism | Phase 2 | Status: COMPLETED | Results posted: 2017-04-11